Summit Therapeutics Plc

Summit Therapeutics (SUMM)

Company name:Summit Therapeutics Plc
EPIC:SUMMTrading Currency:GBX
Market Sector:AIMPISIN:GB00BN40HZ01
Market Segment:ASX1Share Type:DE
WWW Address:Description:ORD 1P
 Price Price Change [%] Bid Offer Open High Low Volume
 20.50 0.0 [0.00] 18.00 23.00 - - - -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 68.85 335.87 0.09 8.71 - 2.35 - -

Summit Therapeutics Key Figures

(at previous day's close)
Market Cap.68.85m
Shares In Issue335.87m
Prev. Close20.50
PE Ratio2.35 
Dividend Yield-%
EPS - basic8.71p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-8.00p
Return On Equity (ROE)17.69%
Operating Margin11.70%
PEG Factor0.01 
EPS Growth Rate180.00%
Dividends PS Growth Rate-%
Net Debt-9.65m
Gross Gearing28.82%
Quick Assets46.83m
Net Working Capital33.94m
Intangibles / Fixed Assets95.27%
Turnover PS12.83p
Pre-Tax Profit PS1.50p
Retained Profit PS2.25p
Cash PS8.01p
Net Cash PS4.17p
Net Tangible Asset Value PS *8.99p
Net Asset Value PS12.69p
Spread5.00 (21.74%) 

Summit Therapeutics Balance Sheet


Share Price Performance

Sorry No Data Available

Share Price Chart (5 years)

Summit Therapeutics Historic Returns

Sorry No Data Available

Summit Therapeutics Key Management Ratios

Summit Therapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio2.35 
Tobin's Q Ratio 0.89 
Tobin's Q Ratio (excl. intangibles)1.21 
Dividend Yield-%
Market-to-Book Ratio1.61 
Price-to-Pre-Tax Profit PS13.66 
Price-to-Retained Profit PS9.13 
Price-to-Cash Flow PS-2.56 
Price-to-Sales PS1.60 
Price-to-Net Tangible Asset Value PS2.28 
Price-to-Cash PS2.56 
Net Working Capital PS10.10 
Price Pct to Working Capital PS2.03%
Earnings Yield42.50%
Average PE1.79 
Years in average1 
PE to PE average131.33%

Summit Therapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio9.29%
Debt-to-Equity Ratio0.10 
Debt-to-Equity Ratio (excl. Intgbl)0.14 
Debt-to-Equity Market Value0.06 
Net Gearing-16.12%
Net Gearing (excl. Intangibles)-20.35%
Gross Gearing28.82%
Gross Gearing (excl. Intangibles)36.38%
Gearing Under 1 Year21.53%
Gearing Under 1 Year (excl. Intgbl)27.18%
(Liquidity Ratios)
Net Working Capital to Total Assets56.66%
Current Ratio3.63 
Quick Ratio (Acid Test)3.63 
Liquidity Ratio2.09 
Cash & Equiv/Current Assets57.47%
(Solvency Ratios)
Enterprise Value46.30m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.25 
Total Debt/Sales0.40 
Total Debt/Pre-Tax Profit3.42 
Total Debt17.26m
Total Debt/Net Current Assets0.51%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs7 
Beta (60-Mnth)Beta (36-Mnth)

Summit Therapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)10.73%
Return On Assets (ROA)9.73%
Net Profit Margin17.50%
Assets Turnover0.56 
Return On Equity (ROE)17.69%
Return On Investment (ROI)13.55%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio21.58%
Net Income Of Revenues17.50%
(Asset Utilisation Multiples)
Shareholders Equity Turnover1.23 
Fixed Assets Turnover2.02 
Current Assets Turnover0.77 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales1.80 
Debt Collection Period205.38Days

Summit Therapeutics Dividends

Sorry No Data Available

Summit Therapeutics Fundamentals

 31 Jan 2016 (USD)31 Jan 2017 (USD)31 Jan 2018 (USD)31 Jan 2019 (USD)
pre tax profit-28.58-1,388.48%-32.35-1,116.04%-15.46-42.85%6.6111.70%m
attributable profit-24.24-1,177.75%-26.86-926.53%-10.12-28.05%9.8917.50%m
retained profit-24.24-1,177.75%-26.86-926.53%-10.12-28.05%9.8917.50%m
eps - basic-41.00 -44.00 -15.00 12.00 
eps - diluted-41.00 -44.00 -15.00 12.00 
dividends per share- - - - 

Summit Therapeutics Balance Sheet

 31 Jan 2016 (USD)31 Jan 2017 (USD)31 Jan 2018 (USD)31 Jan 2019 (USD)
 31 Jan 2016 (USD)31 Jan 2017 (USD)31 Jan 2018 (USD)31 Jan 2019 (USD)
fixed assets fixed assets0.120.33%0.150.31%1.151.50%0.811.03%m
intangibles intangibles5.8716.50%5.2011.00%24.5031.99%16.3120.78%m
fixed investments fixed investments--%--%--%--%m
current assets - other current assets - other--%--%--%--%m
stocks stocks--%--%--%--%m
debtors debtors6.4618.15%6.6414.03%22.4029.26%26.1133.25%m
cash & securities cash & securities23.1365.02%35.3274.66%28.5337.25%35.2844.94%m
creditors - short creditors - short4.5512.79%13.7128.99%26.8835.11%16.9021.53%m
creditors - long creditors - long1.042.94%37.9980.30%35.6846.59%5.727.29%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves29.9784.28%-4.40-9.29%14.0118.30%55.8871.18%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

Summit Therapeutics Cash Flow Statement

31 Jan 2016 (USD)31 Jan 2017 (USD)31 Jan 2018 (USD)31 Jan 2019 (USD)
Operating CF-24.3715.28-20.84-35.20m
Pre-Financing CF-24.4215.18-28.28-35.61m
Retained CF6.9715.70-8.558.31m

Summit Therapeutics Brokers

Evolution Securities LimitedMarket Maker(MMF)Broker/DealerEVOEVBGGB21MMT
Panmure Gordon (UK) LimitedMarket Maker(MMF)Broker/DealerPMURPMURGB2L
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC
ADVFN Advertorial
Your Recent History
Summit The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210725 22:52:08